Influenza and pneumococcal vaccination and the risk of COVID-19: A systematic review and meta-analysis Georgia G. Kapoula^{1, 2}, Konstantina E. Vennou¹ and Pantelis G. Bagos^{1*} ¹ Department of Computer Science and Biomedical Informatics, University of Thessaly, Lamia, 35131, Greece ² Department of Biochemistry, General Hospital of Lamia, Lamia 35100, Greece *Correspondence to: pbagos@gmail.com

ABSTRACT

21

22

23

24

25

26

27

28

29

30

31

32

33

34

35

36

37

38

39

40

41

42

A number of studies have investigated the potential non-specific effects of some routinely administered vaccines (e.g. influenza, pneumococcal) on COVID-19 related outcomes, with contrasting results. In order to elucidate this discrepancy, we conducted a systematic review and meta-analysis to assess the association between seasonal influenza vaccination and pneumococcal vaccination with SARS-CoV-2 infection and its clinical outcomes. PubMed and medRxiv databases were searched, up until November 2021. Random effects model was used in the meta-analysis to pool odds ratio (OR) and adjusted estimates with their 95% confidence intervals (CIs). Heterogeneity was quantitatively assessed using the Cohran's Q and the I^2 index. Subgroup analysis, sensitivity analysis and assessment of publication bias were performed for all outcomes. In total 38 observational studies were included in the meta-analysis and there was substantial heterogeneity. Influenza and pneumococcal vaccination were associated with lower risk of SARS-Cov-2 infection (OR: 0.80, 95% CI: 0.75-0.86 and OR: 0.70, 95% CI: 0.57-0.88, respectively). Regarding influenza vaccination, it seems that the majority of studies did not properly adjust for all potential confounders, so when the analysis was limited to studies that adjusted for age, sex, comorbidities and socioeconomic indices, the association diminished. This is not the case regarding the pneumococcal vaccination, for which even after adjustment for such factors the association persisted. Regarding harder endpoints such as ICU admission and death, current data do not support the association. Possible explanations are discussed, including trained immunity, inadequate matching for socioeconomic indices and possible coinfection.

- 45 **Keywords:** Influenza vaccine; pneumococcal vaccine; SARS-CoV-2; systematic
- 46 review; meta-analysis.

INTRODUCTION

48

49

50

51

52

53

54

55

56

57

58

59

60

61

62

63

64

65

66

67

68

69

70

71

In 2020 in Wuhan, China cases of pneumonia were reported [1], caused by the SARS-CoV-2, which is a coronavirus (CoV) which lead to a pandemic outbreak. The coronaviruses belong in the *Nidovirales* order and in the *Coronaviridae* family, which has four genera divisions, the alpha, beta, gamma, and delta coronaviruses. All coronaviruses contain very large genomes, are enveloped, and non-segmented positive-sense ribonucleic acid (RNA) viruses [2]. Coronaviruses in humans mainly cause respiratory diseases, there are many viruses in this family with a large spectrum of diseases from the less-severe common cold to serious and highly fatal diseases such as the Severe Acute Respiratory Syndrome (SARS) and the Middle East Respiratory Syndrome (MERS). SARS-CoV-2 is a beta coronavirus in the same subgenus with the SARS-CoV-2 and shares RNA with it as well as with the MERS-CoV [3]. The novel coronavirus that we are facing can cause severe disease, a syndrome termed COVID-19. In 1st of April 2022 there have been 486,761,597 confirmed cases and 6,142,735 confirmed deaths worldwide [4]. Seasonal influenza is another acute respiratory infection caused by the influenza viruses. Influenza viruses are part of the Orthomyxoviridae family, in which there are three main genera A, B and C [5]. They are RNA viruses with segmented, negative-strand genome. The diseases caused by influenza have a large range from mild to more severe and even death in high | risk groups [6]. As one can see both diseases are respiratory viral diseases, they co-exist at the same period and they can be clinically indistinguishable (fever, cough, nasal congestion or rhinorrhea, myalgia etc.) [7]. Another respiratory infection is pneumonia. The main causes of pneumonia are viruses, bacteria and fungi. One of the most common bacteria which cause

pneumonia (mainly in children) is *Streptococcus pneumonia* [8]. Some studies have shown co-infection of COVID-19 and influenza or COVID-19 and pneumonia [9].

One step towards the end of the pandemic is vaccination. There are ten vaccines approved by WHO [10]. Although many non SARS-CoV-2 vaccines have been tested for preventing SARS-CoV-2 infection or having a protective effect in the severity of the disease. The booster Bacillus Calmette-Guérin (BCG) vaccine was suggested, by many studies and even by a meta-analysis, to have beneficial effects on preventing COVID-19 infection [11-13]. Some preliminary studies suggest some protection against SARS-CoV-2 to be conferred from vaccination to other pathogens such as influenza [14] while others have produced contrasting results [15]. In this regard, we conducted a systematic review and meta-analysis to assess the overall association between influenza and pneumococcal vaccination and SARS-CoV-2 infection.

MATERIALS and METHODS

72

73

74

75

76

77

78

79

80

81

82

83

84

85

- A comprehensive search was performed to identify papers investigated influenza and
- pneumococcal vaccination and SARS-CoV-2 infection and severity of the disease.
- 89 PubMed [16] and medRxiv [17] were investigated for relevant research articles.
- 90 The search terms for influenza vaccination were: ("Influenza Vaccines" OR
- 91 "influenza vaccine" OR "flu vaccine" OR "anti-flu vaccine") AND ("sars-cov2" OR
- 92 "covid-19" OR "2019-ncov" OR "2019nconv" OR "sars-cov2" OR "covid-19") in
- PubMed and "influenza vaccine" (abstract or title, match all words) in medRxiv. For
- 94 the pneumococcal vaccination were: ("pneumococcal Vaccines" OR "pneumococcal
- 95 vaccine") AND ("sars-cov2" OR "covid-19" OR "2019-ncov" OR "2019nconv" OR
- "sars-cov2" OR "covid-19") in PubMed and "pneumococcal vaccine" (abstract or title,

98

99

100

101

102

103

104

105

106

107

108

109

110

111

112

113

114

115

116

117

118

119

120

121

match all words) in medRxiv. To avoid selection bias no filter was applied in language, year, method etc. This systematic review was performed according to Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines [18], the STROBE Statement checklist [19] and other general guidelines [20]. The search was performed until 01/11/2021. The information that was extracted from the selected studies was: Authors, Title, Year of publication, Country in which it was conducted, Study Design, Study population, Sample size, Gender, Comorbidities, COVID-19 outcome, the effect size related to relevant outcomes (e.g. OR, HR, RR) and other potentially relevant information. Since the risk for COVID-19 varies largely according to risk factors, studies not including adjusted odds ratio (OR), adjusted hazard ratio (HR) or adjusted relative risk (RR) as their effect size were excluded. We requested that the effect sizes were adjusted mainly for gender, age, race, comorbidities, smoking status etc. The main inclusion criteria were: a) vaccination period for influenza or pneumococcal from autumn 2019 until autumn 2020, b) confirmed COVID-19 infection with either real-time PCR, or serologic test, or according to WHO definition or laboratory confirmation (not specified), c) participants being adults and d) comparison of people infected with COVID-19 against non-infected ones using an adjusted estimate of OR, HR or RR (see above). In order to assess the association between the two vaccines (influenza and pneumococcal) and COVID-19 outcome (infection, death, hospitalization, etc.), a random effects meta-analysis was performed, for each outcome, using as effect size the adjusted OR, or adjusted RR/HR, combined with their 95% confidence interval (CI) [21]. The between studies heterogeneity of the pooled estimates was quantified by means of the chi-square-based Cochran's Q statistic and the consistency index (I^2)

[22]. To assess publication bias, the rank correlation method of Begg and Mazumdar [23], and the fixed effects regression method of Egger [24] were applied. Subgroup analyses were performed to investigate the effect of various study level characteristics. Sensitivity analyses were performed by omitting one study at a time to assess studies with notable impact and examine the robustness of the overall effect. For all statistical analyses performed, the statistical software package STATA 13 [25] was used and results with p-value <0.05 were considered statistically significant.

RESULTS

Study selection and study characteristics

The literature search from the two databases identified a total of 768 related to the influenza vaccination and 86 records for the pneumococcal vaccination search. After reading the titles for excluding duplicates, 674 and 79 unique publications remained for influenza and pneumococcal vaccination, respectively. The simultaneously titles and abstracts review led to a further rejection of 697 publications. The remaining 56 articles were read in full copy, as well as the citations of the retrieved articles. Finally, 38 publications met all the inclusion criteria for the quantitative analysis and were included in the final systematic review and meta-analysis. The PRISMA flow diagram of the study selection procedure is shown in Figure 1.

Among the included publications, 22 studies focused on the association between influenza vaccination and the risk of SARS-CoV-2 infection and 10 studies on the association between pneumococcal vaccination and the risk of SARS-CoV-2 infection. These studies comprised a total of 55,917,587 individuals (COVID-19 patients and non-COVID patients).

147

148

149

150

151

152

153

154

155

156

157

158

159

160

161

162

163

164

165

166

167

168

169

Out of the 38 publications included in the meta-analysis, 19 publications assessed the association of the influenza vaccination and COVID-19 clinical outcomes. The different outcomes included: a) need of hospitalization involving 15 studies with 55,881,321 individuals (13,123,605 vaccinated and 42,758,116 unvaccinated patients) b) administration of mechanical ventilation/invasive respiratory oxygen support described in 4 studies encompassing 255,735 patients, c) intensive care unit admission. This outcome was assessed in 11 studies involving 446,924 vaccinated and not vaccinated patients and d) mortality which was assessed in 18 studies involving 407,409 vaccinated and not vaccinated COVID-19 patients. Moreover, 4 studies assessed the association between pneumococcal vaccination and hospitalization enrolling 4,310 patients of which 1,333 were vaccinated and 2,977 were not vaccinated. Finally, 3 studies examined the association between pneumococcal vaccination and intensive care unit involving 1,231 patients (921 non-vaccinated Vs 310 vaccinated). The baseline characteristics of the included studies are listed in Table 1 (influenza vaccination and SARS-CoV-2 infection), Table 2 (influenza vaccination and clinical outcomes) and Table 3 (pneumococcal vaccination and SARS-CoV-2 infection and clinical outcomes). Most studies enrolled individuals from the general population. Among them, five studies had as a population study health workers [26-30], one study involved only pregnant women [31], another study included only transplant recipients [32] and four studies were performed in older adults (age >65) [33-36]. The laboratory method (rt-PCR) used to diagnose of the disease was common in most of the included studies. The adjustment variables varied across studies with age, sex and comorbidities being the most common ones reflecting the known COVID-19 risk factors. Studies which did not contain adjusted estimates (OR or RR/HR) as well as ecological studies were excluded from the meta-analysis and are summarized in Supplementary Table 1.

The association between influenza vaccination and SARS-CoV-2 infection

170

171

172

173

174

175

176

177

178

179

180

181

182

183

184

185

186

187

188

189

190

191

192

193

The results of the random effects analysis are summarized in Table 4. The association of the influenza vaccination and SARS-CoV-2 infection is presented graphically in the forest plot in Figure 2. Influenza vaccination is shown to be associated with lower risk of SARS-CoV-2 infection (random effects model: pooled estimate 0.80, 95% CI: 0.75-0.86). The results of the statistical tests for publication bias (Begg's, Egger's test) are shown in Table 4. Both tests showed no evidence of publication bias for the pooled estimates of the association between influenza vaccination and SARS-CoV-19 infection (p-value >0.05). In the leave-one-out sensitivity analyses regarding the association between influenza vaccination and SARS-CoV-2 infection, the results showed that no individual study influenced the overall effect estimate. The between-studies heterogeneity was substantial with $I^2=70.1\%$. In order to investigate the high degree of heterogeneity we performed subgroup analysis investigating the potential effect of study-level characteristics (study design, study population, effect size, adjustment factors, method for assessment of COVID-19 and continent). However, none of these factors seemed to play an important role, since in all cases the results of the subgroup analysis are quite close to the overall estimate (Table 5). It is worth noting however, that the association was diminished when the analysis was restricted to the 6 studies that adjusted for age, sex, comorbidities and

some indices of socioeconomic status (like residence, income or education).

195

196

197

198

199

200

201

202

203

204

205

206

207

208

209

210

211

212

213

214

215

216

217

218

Moreover, two studies (Debisarum et al. [37], Erismis et al [30]) were scrutinized further as in their analysis they used only age and sex, respectively as adjustment variables. However, when both were excluded from the meta-analysis and the overall meta-analysis was repeated, the results did not differ from the overall estimate: OR 0.81 (95% CI: 0.75-0.87). The association between influenza vaccination and COVID-19 clinical outcomes The results of the meta-analysis that was conducted separately for each clinical outcome of interest are shown in Table 4. The results suggest a potential association between influenza vaccination and hospitalization (OR: 0.88, 95% CI: 0.81-0.96) and mechanical ventilation/invasive respiratory support (OR: 0.73, 95% CI: 0.58-0.92), but not with ICU admission (OR: 0.96, 95% CI: 0.88-1.06) and mortality (OR: 0.90, 95% CI:0.81-1.01). Both Begg's and Egger's tests showed no evidence of publication bias for the pooled estimates of the association between influenza vaccination and COVID-19 related clinical outcomes (all p-values >0.05). The summary of the publication bias tests is presented in Table 4. Figure 3 represents the forest plot for the association between influenza vaccination and COVID-19 related hospitalization and between influenza vaccination and mortality. In the sensitivity analyses that followed, the pooled estimates were consistent when any single study was omitted. Subgroup analysis was performed to explain the between studies heterogeneity for the association of influenza vaccination and COVID-19 clinical outcomes (Table 6). Study design was not used as a variable in this subgroup analysis, as the majority of the studies were cohort studies with the exception of one cross-sectional study in the hospitalization outcome and two cross-

sectional study investigating the mortality outcome. Study population was also not

220

221

222

223

224

225

226

227

228

229

230

231

232

233

234

235

236

237

238

239

240

241

242

243

used as the majority of the studies involved adults from the general population. Moreover, due to the limited studies reporting adjusted measures of the effect of the association between influenza vaccination and the need of mechanical ventilation, subgroup analysis could not be performed in this case. We also investigated the effect of the study of Greco et al. [38], in which they were significant differences in terms of the age of the vaccinated and non-vaccinated group and the two groups were adjusted only for sex. When the study was excluded from the meta-analysis concerning the association between influenza vaccination and mortality, the results did not significantly differ from the ones in the overall metaanalysis (OR 0.90, 95% CI: 0.81-1.00). The association between pneumococcal vaccination with SARS-CoV-2 infection and its clinical outcomes A meta-analysis of the association between pneumococcal vaccination with SARS-CoV-2 infection, the need of hospitalization and ICU admission was performed. As a result, pneumococcal vaccination was shown to be associated with lower risk of COVID-19 infection (Figure 4, Table 7). The majority of the studies here (7 out of 10) provided estimates adjusted for age, sex, comorbidities and some indices of socioeconomic status (like residence, income or education). Even when we restricted the analysis in this sample the overall effect did not change (OR: 0.61, 95% CI: 0.44-0.85). The results of the meta-analysis regarding pneumococcal vaccination and the need of hospitalization showed that the vaccine seems to be associated with a higher risk for COVID-19 hospitalization. However, only four studies investigated the particular association, and additionally there was evidence for publication bias in this

analysis making the results questionable. Finally, pneumococcal vaccination was not associated with the need of intensive care but as before, only three studies investigated this association.

DISCUSSION

244

245

246

247

248

249

250

251

252

253

254

255

256

257

258

259

260

261

262

263

264

265

266

267

268

Influenza and COVID-19 are different respiratory viral diseases that can be clinically indistinguishable and co-exist at the same period. Some preliminary studies suggest some protection against SARS-CoV-2 to be conferred from vaccination to other pathogens such as influenza [14] while others have produced contrasting result [39]. There is also a limited number of studies that examined the association of the pneumococcal vaccine with the risk of developing SARS-CoV-2 infection and disease severity or risk of death on COVID-19 patients. In order to elucidate this discrepancy, we conducted a systematic review and meta-analysis to assess the association between seasonal influenza vaccination, pneumococcal vaccination and SARS-CoV-2 infection as well as with clinical outcomes related to COVID-19 morbidity and mortality. Our study followed all the available guidelines and ultimately included 38 publications that have evaluated the association of interest (24 studies on SARS-CoV-2 infection). Overall, our results indicate that influenza vaccination seems to be associated with lower risk for COVID-19 infection, as well as against hospitalization and mechanical ventilation, but no significant effect was found against "harder" endpoints like ICU admission and mortality. Specifically, the results of the metaanalysis showed that people vaccinated between autumn 2019 to autumn 2020, had up to 20% lower risk of COVID-19 infection. Similarly, if vaccinated individuals were infected by SARS-CoV-2 the risk of hospitalization would be reduced by 12% and the need of mechanical ventilation by 27%. As far as the pneumococcal vaccination is

concerned, the results show that it has a protective effect against SARS-CoV-2 infection while it does not seem to have the same effect on COVID-19 hospitalization or ICU admission, although these analyses included a small number of studies.

269

270

271

272

273

274

275

276

277

278

279

280

281

282

283

284

285

286

287

288

289

290

291

292

293

During the last year, two systematic review and meta-analyses were published or the same topic, but the included studies were fewer that the ones included in our meta-analysis [40, 41]. In the study of Wang et al. a total of 9, 3, 2, and 3 studies were included for the association of influenza vaccination and SARS-CoV-2 infection, hospitalization, ICU admission and mortality respectively. The authors stated in their results that "the association between influenza vaccination and COVID-19 clinical outcomes was not statistically significant by random effects model while the results by fixed effects model was somehow significant". They attribute this result to "the substantial heterogeneity between the small number of studies and participants involved in each outcome". In their meta-analysis, Zeynali Bujani et al. [41] included 9 studies for the association of influenza vaccine and COVID-19, among which were two studies excluded from our meta-analysis. The particular studies, of Jedi et al. [42] and Caban-Marntinez et al. [43], were excluded as they reported effect sizes based on crude counts. Such data clearly violated our inclusion criteria, as we attempted to minimize the potential confounding by using only adjusted estimates. In addition, the study of Skowronski et al. [44] a retrospective analysis from Canada, which involved specimens collected during the 2010-2011 to 2016-2017 seasons, when specimens were tested for both influenza and non-influenza respiratory viruses (NIRVs), including some seasonal coronaviruses but not specific and exclusively SARS-CoV-2. We performed the meta-analysis following strict criteria, we included all the available data and investigated every study level covariate that may have influenced

the outcome. Nevertheless, the between studies heterogeneity was high and the

295

296

297

298

299

300

301

302

303

304

305

306

307

308

309

310

311

312

313

314

315

316

317

318

attempts to explain it using study-level covariates did not reveal anything of importance. In any case, heterogeneity is expected for many reasons that include the design of the study, the studied population, the sampling method, as well as the testing and vaccination policies in each country. In our analysis we included studies in which the seasonal influenza vaccination was administered between 2019 and 2020. The type of influenza vaccination and the exact date when the vaccines were administered was not specified in all studies and as influenza varies across years, results should be interpreted with caution regarding different influenza seasons. The testing policy implemented in each country also varied in the included studies, using different diagnostic tests. Most of the studies used molecular diagnosis with rt-PCR, few used antibody testing whereas some studies did not specify the laboratory method used. Furthermore, we must consider that national influenza immunization policies can vary significantly from country to country. These differences arise from insufficient information of the relevance of influenza infection from a clinical, social and economic point of view [45]. Our findings suggest that both vaccines are associated with a lower risk for SARS-CoV-2 infection, but not with "harder" endpoints such as ICU admission and death. The influenza vaccine was found additionally to be associated with decreased risk for hospitalization and need for mechanical ventilation. This association is counter-intuitive at first sight and hence needs to be explained. It is worth mentioning that BCG vaccine, a vaccine primarily used against tuberculosis (TB), which is mandatory in several countries [30], seems also to has a protective effect since a meta-analysis of data from 160 countries has shown that when the BCG vaccine coverage was over 70% there was a reduction in the COVID-19 infections [12]. Also some studies have found that mandatory BCG vaccination is associated with a

320

321

322

323

324

325

326

327

328

329

330

331

332

333

334

335

336

337

338

339

340

341

342

343

flattening of the curve in the spread of COVID-19 [46] and that differences in mortality produced by COVID-19 across countries are correlated with a country's BCG vaccination policy [47, 48]. However, these data come from ecological studies and thus need to be interpreted with caution. Cross-reactivity is unlikely to exist between SARS-CoV-2 and influenza viruses, and thus other potential explanations should be considered. There is, for instance, some evidence that vaccines developed for a specific pathogen may have a wider role in protection against unrelated pathogens. Such cases include Bacillus Calmette-Guérin (BCG), measles and influenza [49]. The underlying mechanisms for such non-specific actions remain poorly understood, but a plausible suggested mechanism includes the induction of innate immune response following live attenuated vaccination, in a way that is independent of memory cells (T or B cells). This type of immunity, termed "trained innate immunity", may confer non-specific protection against different pathogens, by inducing upregulation of recognition receptors (such as toll-like receptors) and secretion of proinflammatory cytokines (such as TNF-alpha and IL-6) in peripheral blood leucocytes and functional changes in natural killer cells [37, 50]. Nevertheless, other more plausible explanations should not be ruled out. The studies included in this meta-analysis are heterogeneous in many respects including their design, the study population and the inclusion criteria. In terms of their design all included studies were observational, so the risk of possible confounding should be considered. In such cases, when some important risk factors do exist (such as age, gender, and comorbidities), it would be unwise to perform the meta-analysis including crude estimates. However, even though we included only adjusted estimates, or studies with matched groups, the factors for which the adjustment were performed were not the same across studies. For instance, most studies adjusted for age and sex, others for several comorbidities (and even in this case, not for the same comorbidities), and some others for additional factors such as area of residence or socioeconomic status. In the subgroup analysis we tried to investigate this effect, but we were unable to find systematic differences across studies.

344

345

346

347

348

349

350

351

352

353

354

355

356

357

358

359

360

361

362

363

364

365

366

367

368

Socioeconomic factors, such as educational level, household size and income have been reported to have a significant effect on the probability of being vaccinated against influenza [51], whereas the same factors have been consistently shown to play significant role in COVID-19 morbidity and mortality [52-54]. It is possible therefore to speculate that individuals who get vaccinated may pay more attention to their health status and lifestyle, and subsequently, they might have been more compliant to the various non-pharmaceutical interventions suggested for COVID-19 prevention, such as social distancing, wearing masks, hand hygiene practices and use of protective equipment, leading to a reduced potential risk of infection. Following the same rationale, since vaccinated individuals are under-represented in the lower socioeconomic categories (e.g. those who cannot work from home, those who need to use public transportation, or live in crowded households and so on), then these factors might explain the observed increased risk of getting COVID-19. This interpretation is also consistent with the results suggesting that vaccinated individuals are at increased risk of SARS-CoV-2 infection, but not at risk of ICU admission or death, since in these cases the comparison was made among those that were already infected, and the supposed confounding effect has been potentially removed.

Interestingly, when the analysis was restricted to the studies that adjusted for age, sex, comorbidities and some indices of socioeconomic status (like area of residence, income or education), the association of influenza vaccination with the risk

of SARS-CoV-2 infection was diminished. Thus, future and more carefully designed studies, that will adjust more thoroughly for socioeconomic indices, should be pursuit to investigate this hypothesis. However, this observation does not seem to hold regarding the association of pneumococcal vaccination with SARS-CoV-2 infection, since the statistically significant association persists even after restricting the analysis in the studies that adjusted for the same factors. We need to mention, that even though the studies regarding pneumococcal vaccination were fewer in total, the majority of them provided estimates adjusted for socioeconomic indices, which is in contrast to what is the case for studies of influenza vaccine.

Most respiratory viral diseases may have as complication bacterial coinfections, or secondary infections (super-infections), which can worsen the clinical outcome increasing thus morbidity and mortality. However, it has been argued that the proportion of COVID-19 patients with bacterial coinfections and/or super-infections may be lower compared to what we have seen in patients suffering from influenza [55-57]. Nevertheless, since vaccination is beneficial per se, it has been suggested that pneumococcal vaccination can, to some extent, provide additional protection to the COVID-19 patients reducing the morbidity and mortality [58]. Animal studies have also shown that an initial SARS-CoV-2 infection can increase susceptibility and pathogenicity to bacterial coinfection [59]. The limited number of available studies regarding the association of pneumococcal vaccination with hospitalization, ICU admission and death, did not allow us to test this hypothesis, but as we said the association of vaccination with SARS-CoV-2 infection remained significant even after adjustment for sex, age, comorbidities and socioeconomic indices, and this should be investigated in future studies.

Conflict of Interest: none declared

REFERENCES

- Huang, C., et al., Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. The lancet, 2020. 395(10223): p. 497-506.
- 398 2. Maier, H.J., E. Bickerton, and P. Britton, *Preface. Coronaviruses.* Methods Mol Biol, 2015. **1282**: p. v.
- 400 3. Lu, R., et al., Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet (London, England), 2020. **395**(10224): p. 565-574.
- 403 4. (WHO), W.H.O. *Origin of SARS-CoV-2*. 2019; WHO/2019-404 nCoV/FAQ/Virus_origin/2020.1].
- 405 5. Bouvier, N.M. and P. Palese, *The biology of influenza viruses*. Vaccine, 2008. **26 Suppl 4**(Suppl 4): p. D49-53.
- 407 6. (WHO), W.H.O. Influenza (Seasonal). 2018.
- Jiang, C., et al., Comparative review of respiratory diseases caused by coronaviruses and influenza A viruses during epidemic season. Microbes Infect, 2020. 22(6-7): p. 236-244.
- 411 8. (WHO), W.H.O. Pneumonia. 2021.
- 412 9. Xing, Q.-s., et al., *Precautions are Needed for COVID-19 Patients with Coinfection of Common Respiratory Pathogens.* medRxiv, 2020: p. 2020.02.29.20027698.
- 414 10. Team, V.G.C.V.T. *COVID-19 Vaccine Tracker* 2022; Available from https://covid19.trackvaccines.org/.
- 416 11. Amirlak, L., et al., Effectiveness of booster BCG vaccination in preventing Covid-19 infection. Hum Vaccin Immunother, 2021: p. 1-3.
- 418 12. Joy, M., et al., *Is BCG associated with reduced incidence of COVID-19? A meta-*419 regression of global data from 160 countries. Clinical epidemiology and global health, 420 2021. **9**: p. 202-203.
- 421 13. Dolgikh, S., Hospitalization Data Supports Correlation of Lower Covid-19 Severity vs.
 422 Universal BCG Immunization in the Early Phase of the Pandemic. medRxiv, 2021.
- 423 14. Mosaddeghi, P., et al., *Harnessing the non-specific immunogenic effects of available vaccines to combat COVID-19.* Hum Vaccin Immunother, 2021. **17**(6): p. 1650-1661.
- Kissling, E., et al., Absence of association between 2019-20 influenza vaccination
 and COVID-19: Results of the European I-MOVE-COVID-19 primary care project,
 March-August 2020. Influenza Other Respir Viruses, 2021. 15(4): p. 429-438.
- 428 16. PubMed Help [Internet], in Bethesda (MD): National Center for Biotechnology Information (US); 2005-. PubMed Help. [Updated 2018 Mar 28].
- 430 17. medRxiv. 2019.
- 431 18. Moher, D., et al., *Preferred reporting items for systematic reviews and meta-analyses:* the PRISMA statement. PLoS Med, 2009. **6**(7): p. e1000097.
- 433 19. Morton, S.C., et al., Standards and guidelines for observational studies: quality is in the eye of the beholder. Journal of Clinical Epidemiology, 2016. **71**: p. 3-10.
- 435 20. Forero, D.A., et al., *Ten simple rules for carrying out and writing meta-analyses*. PLoS computational biology, 2019. **15**(5): p. e1006922-e1006922.
- 437 21. DerSimonian, R. and N. Laird, *Meta-analysis in clinical trials*. Control Clin Trials, 1986. **7**(3): p. 177-88.
- 439 22. Higgins, J.P., et al., *Measuring inconsistency in meta-analyses.* Bmj, 2003. **327**(7414): p. 557-60.
- 441 23. Begg, C.B. and M. Mazumdar, *Operating characteristics of a rank correlation test for publication bias.* Biometrics, 1994. **50**(4): p. 1088-101.
- Egger, M., et al., Bias in meta-analysis detected by a simple, graphical test. Bmj, 1997. **315**(7109): p. 629-34.
- 445 25. StataCorp, Stata 13 Base Reference Manual. 2013, College Station, TX: Stata Press. 446 .
- 447 26. Martinez-Baz, I., et al., *Influenza Vaccination and Risk of SARS-CoV-2 Infection in a Cohort of Health Workers.* Vaccines (Basel), 2020. **8**(4).
- 449 27. Massoudi, N. and B. Mohit, A Case-Control Study of the 2019 Influenza Vaccine and Incidence of COVID-19 Among Healthcare Workers. J Clin Immunol, 2021. **41**(2): p. 324-334.
- 452 28. Belingheri, M., et al., Association between seasonal flu vaccination and COVID-19 among healthcare workers. Occup Med (Lond), 2020. **70**(9): p. 665-671.

- 454 29. Rivas, M.N., et al., *BCG vaccination history associates with decreased SARS-CoV-2*455 seroprevalence across a diverse cohort of health care workers. J Clin Invest, 2021.
 456 **131**(2).
- 457 30. Erismis, B., et al., *Annual influenza vaccination effect on the susceptibility to COVID-*458 19 infection. Cent Eur J Public Health, 2021. **29**(1): p. 14-17.
- de la Cruz Conty, M.L., et al., *Impact of Recommended Maternal Vaccination Programs on the Clinical Presentation of SARS-CoV-2 Infection: A Prospective Observational Study.* Vaccines (Basel), 2021. **9**(1).
- 462 32. Azzi, Y., et al., COVID-19 infection in kidney transplant recipients at the epicenter of pandemics. Kidney Int, 2020. **98**(6): p. 1559-1567.
- 464 33. Caratozzolo, S., et al., *The impact of COVID-19 on health status of home-dwelling*465 *elderly patients with dementia in East Lombardy, Italy: results from COVIDEM*466 *network.* Aging Clin Exp Res, 2020. **32**(10): p. 2133-2140.
- Huang, K., et al., *Influenza vaccination and the risk of COVID-19 infection and severe illness in older adults in the United States.* Sci Rep, 2021. **11**(1): p. 11025.
- Noale, M., et al., The Association between Influenza and Pneumococcal Vaccinations and SARS-Cov-2 Infection: Data from the EPICOVID19 Web-Based Survey.
 Vaccines (Basel), 2020. 8(3).
- 472 36. Pastorino, R., et al., *Influenza and pneumococcal vaccinations are not associated to COVID-19 outcomes among patients admitted to a university hospital.* Vaccine, 2021. **39**(26): p. 3493-3497.
- 475 37. Debisarun, P.A., et al., *The effect of influenza vaccination on trained immunity: impact on COVID-19.* MedRxiv, 2020.
- 477 38. Greco, S., et al., SARS-CoV-2 infection and H1N1 vaccination: does a relationship 478 between the two factors really exist? A retrospective analysis of a territorial cohort in 479 Ferrara, Italy. Eur Rev Med Pharmacol Sci, 2021. **25**(6): p. 2795-2801.
- 480 39. Kissling, E., et al., Absence of association between 2019-20 influenza vaccination and COVID-19: Results of the European I-MOVE-COVID-19 primary care project, March-August 2020. Influenza and other respiratory viruses, 2021. **15**(4): p. 429-438.
- 483 40. Wang, R., M. Liu, and J. Liu, *The Association between Influenza Vaccination and COVID-19 and Its Outcomes: A Systematic Review and Meta-Analysis of Observational Studies.* Vaccines (Basel), 2021. **9**(5).
- 486 41. Zeynali Bujani, M., et al., *The Effect of Influenza Vaccination on COVID-19 Morbidity,*487 *Severity and Mortality: Systematic Review and Meta-Analysis.* Malays J Med Sci,
 488 2021. **28**(6): p. 20-31.
- 489 42. Jehi, L., et al., *Individualizing Risk Prediction for Positive Coronavirus Disease 2019*490 *Testing: Results From 11,672 Patients.* Chest, 2020. **158**(4): p. 1364-1375.
- 491 43. Caban-Martinez, A.J., et al., *Epidemiology of SARS-CoV-2 antibodies among firefighters/paramedics of a US fire department: a cross-sectional study.* Occup Environ Med, 2020. **77**(12): p. 857-861.
- 494 44. Skowronski, D.M., et al., Influenza Vaccine Does Not Increase the Risk of Coronavirus or Other Noninfluenza Respiratory Viruses: Retrospective Analysis From Canada, 2010-2011 to 2016-2017. Clin Infect Dis, 2020. **71**(16): p. 2285-2288.
- 497 45. Principi, N., et al., *Influenza immunization policies: Which could be the main reasons*498 for differences among countries? Human vaccines & immunotherapeutics, 2018.
 499 **14**(3): p. 684-692.
- 500 46. Berg, M.K., et al., Mandated Bacillus Calmette-Guérin (BCG) vaccination predicts 501 flattened curves for the spread of COVID-19. Science advances, 2020. **6**(32): p. 502 eabc1463.
- 503 47. Miller, A., et al., Correlation between universal BCG vaccination policy and reduced mortality for COVID-19. MedRxiv, 2020.
- 505 48. Singh, S., et al., *BCG vaccination impact on mortality and recovery rates in COVID-*506 19: A meta-analysis. Monaldi Archives for Chest Disease, 2021.
- 507 49. Covián, C., et al., *BCG-induced cross-protection and development of trained immunity: implication for vaccine design.* Frontiers in Immunology, 2019. **10**: p. 2806.
- 509 50. Long, B.R., et al., *Elevated frequency of gamma interferon-producing NK cells in healthy adults vaccinated against influenza virus.* Clinical and Vaccine Immunology, 2008. **15**(1): p. 120-130.

- 51. Endrich, M.M., P.R. Blank, and T.D. Szucs, *Influenza vaccination uptake and* socioeconomic determinants in 11 European countries. Vaccine, 2009. **27**(30): p. 4018-4024.
- 515 52. Rollston, R. and S. Galea, *COVID-19 and the social determinants of health.* 2020, SAGE Publications Sage CA: Los Angeles, CA. p. 687-689.
- 517 53. Patel, J., et al., *Poverty, inequality and COVID-19: the forgotten vulnerable.* Public health, 2020. **183**: p. 110.
- 519 54. Wachtler, B., et al., Socioeconomic inequalities in the risk of SARS-CoV-2 infection— 520 First results from an analysis of surveillance data from Germany. 2020.
- 52. Lansbury, L., et al., *Co-infections in people with COVID-19: a systematic review and meta-analysis.* Journal of Infection, 2020. **81**(2): p. 266-275.
- 523 56. Feldman, C. and R. Anderson, *The role of co-infections and secondary infections in patients with COVID-19.* Pneumonia, 2021. **13**(1): p. 1-15.
- 525 57. Joseph, C., Y. Togawa, and N. Shindo, *Bacterial and viral infections associated with influenza*. Influenza and other respiratory viruses, 2013. **7**: p. 105-113.
- 527 58. Im, H., et al., *Promising Expectations for Pneumococcal Vaccination during COVID-*528 19. Vaccines, 2021. **9**(12): p. 1507.
- 529 59. Smith, A.P., et al., *Time-Dependent Increase in Susceptibility and Severity of Secondary Bacterial Infection during SARS-CoV-2 Infection.* bioRxiv, 2022.
- 531 60. Ragni, P., et al., Association between Exposure to Influenza Vaccination and COVID-532 19 Diagnosis and Outcomes. Vaccines (Basel), 2020. **8**(4).
- 533 61. Vila-Corcoles, A., et al., *Influence of prior comorbidities and chronic medications use*534 on the risk of COVID-19 in adults: a population-based cohort study in Tarragona,
 535 Spain. BMJ Open, 2020. **10**(12): p. e041577.
- 536 62. Green, I., et al., *The association of previous influenza vaccination and coronavirus disease-2019.* Hum Vaccin Immunother, 2021. **17**(7): p. 2169-2175.
- 538 63. Conlon, A., et al., *Impact of the influenza vaccine on COVID-19 infection rates and severity.* Am J Infect Control, 2021. **49**(6): p. 694-700.
- 540 64. Bozek, A., et al., *Impact of influenza vaccination on the risk of SARS-CoV-2 infection*541 *in a middle-aged group of people.* Hum Vaccin Immunother, 2021. **17**(9): p. 3126542 3130.
- Kowalska, M., et al., Association between Influenza Vaccination and Positive SARS CoV-2 IgG and IgM Tests in the General Population of Katowice Region, Poland.
 Vaccines (Basel), 2021. 9(5).
- 546 66. Fernandez-Prada, M., et al., *Personal and vaccination history as factors associated with SARS-CoV-2 infection.* Med Clin (Engl Ed), 2021. **157**(5): p. 226-233.
- 548 67. King, J.P., H.Q. McLean, and E.A. Belongia, *Risk of symptomatic severe acute* 549 respiratory syndrome coronavirus 2 infection not associated with influenza 550 vaccination in the 2019-2020 season. Influenza Other Respir Viruses, 2021. **15**(6): p. 551 697-700.
- 552 68. Pawlowski, C., et al., Exploratory analysis of immunization records highlights 553 decreased SARS-CoV-2 rates in individuals with recent non-COVID-19 vaccinations. 554 Sci Rep, 2021. **11**(1): p. 4741.
- 555 69. Zein, J.G., G. Whelan, and S.C. Erzurum, *Safety of influenza vaccine during COVID-*556 19. Journal of Clinical and Translational Science, 2021. **5**(1).
- Xiang, Y., K.C. Wong, and H.C. So, Exploring Drugs and Vaccines Associated with
 Altered Risks and Severity of COVID-19: A UK Biobank Cohort Study of All ATC
 Level-4 Drug Categories Reveals Repositioning Opportunities. Pharmaceutics, 2021.
 13(9).
- Alkathlan, M., et al., Trends, Uptake, and Predictors of Influenza Vaccination Among
 Healthcare Practitioners During the COVID-19 Pandemic Flu Season (2020) and the
 Following Season (2021) in Saudi Arabia. J Multidiscip Healthc, 2021. 14: p. 2527 2536.
- 72. Pedote, P.D., et al., *Influenza Vaccination and Health Outcomes in COVID-19 Patients: A Retrospective Cohort Study.* Vaccines (Basel), 2021. **9**(4).
- Gobbato, M., et al., Clinical, demographical characteristics and hospitalisation of
 3,010 patients with Covid-19 in Friuli Venezia Giulia Region (Northern Italy). A
 multivariate, population-based, statistical analysis. Epidemiol Prev, 2020. 44(5-6
 Suppl 2): p. 226-234.

- 571 74. Yang, M.J., et al., *Influenza Vaccination and Hospitalizations Among COVID-19 Infected Adults.* J Am Board Fam Med, 2021. **34**(Suppl): p. S179-S182.
- Massari, M., et al., Association of Influenza Vaccination and Prognosis in Patients
 Testing Positive to SARS-CoV-2 Swab Test: A Large-Scale Italian Multi-Database
 Cohort Study. Vaccines (Basel), 2021. 9(7).
- 576 76. Wilcox, C.R., N. Islam, and H. Dambha-Miller, Association between influenza 577 vaccination and hospitalisation or all-cause mortality in people with COVID-19: a 578 retrospective cohort study. BMJ Open Respir Res, 2021. **8**(1).
- 579 77. Ilic, I., et al., *Pneumonia in medical professionals during COVID-19 outbreak in cardiovascular hospital.* Int J Infect Dis, 2021. **103**: p. 188-193.
- 78. Taghioff, S.M., et al., Examining the potential benefits of the influenza vaccine against
 SARS-CoV-2: A retrospective cohort analysis of 74,754 patients. PLoS One, 2021.
 16(8): p. e0255541.
- Fink, G., et al., *Inactivated trivalent influenza vaccination is associated with lower mortality among patients with COVID-19 in Brazil.* BMJ Evid Based Med, 2020.
- 586 80. Demkina, A.E., et al., *Risk factors for outcomes of COVID-19 patients: an observational study of 795 572 patients in Russia.* medRxiv, 2020.
- 588 81. Candelli, M., et al., *Effect of influenza vaccine on COVID-19 mortality: A retrospective study.* Internal and emergency medicine, 2021. **16**(7): p. 1849-1855.
- Fernandez Ibanez, J.M., et al., *Influence of influenza vaccine and comorbidity on the* evolution of hospitalized COVID-19 patients. Med Clin (Barc), 2021.
- 592 83. Giannoglou, D., et al., *Predictors of mortality in hospitalized COVID-19 patients in Athens, Greece.* medRxiv, 2020.
- 594 84. Ortiz-Prado, E., et al., *Epidemiological, socio-demographic and clinical features of the*595 early phase of the COVID-19 epidemic in Ecuador. PLoS Negl Trop Dis, 2021. **15**(1):
 596 p. e0008958.



PRISMA 2009 Flow Diagram




Figure 1 The PRISMA flow diagram for the included studies





Figure 2 Forest plot for the association between influenza vaccination and SARS-Cov-2 infection






Figure 3 Left: Forest plot for the association between influenza vaccination and COVID-19 related hospitalization and Right: Forest plot for the association between influenza vaccination and mortality




Figure 4 Forest plot for the association between pneumococcal vaccination and SARS-CoV-2 infection

medRxiv preprint doi: https://doi.org/10.1101/2022.06.30.22277089; this version posted June 30, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

All rights reserved. No reuse allowed without permission.

Table 1 Baseline characteristics of the 21 publications, involving 22 studies that assessed the association between influenza vaccination and SARS-CoV-2 infection.

First Author's name	Year of publication	Country	study design/study population	Identification of COVID-19	Sample size	Effect size	Adjusted estimate	Adjusted factors
M. Noale et al. [35]	2020	Italy	Cross-sectional study/Adults- general population	rt-PCR	6,061	OR	0.85 (95% CI: 0.74-0.98)	age, sex, self-reported comorbidities, education, area of residence, smoking status
M. Noale et al. [35]	2020	Italy	Cross-sectional study/Old adults	rt-PCR	619	OR	0.87 (95% CI: 0.59-1.28)	sex, age, self-reported comorbidities, education, area of residence, smoking status
I. Martínez-Baz et al. [26]	2020	Spain	Prospective cohort study/Health workers	rt-PCR or Antibody Rapid test	9,745	OR	1.07(95% CI: 0.92-1.24)	age, sex, major chronic conditions, profession, and any ILI diagnosis in the previous five years.
P. Ragni et al. [60]	2020	Italy	Case control study/Adults-general population	rt-PCR	17,608	OR	0.89 (95% CI: 0.80-0.99)	age, sex, Charlson index score and time of the swab test
M. Belingheri et al. [28]	2020	Italy	Retrospective cohort study/Health workers	rt-PCR	3,520	OR	0.41 (95% CI: 0.07-2.39)	age, gender, number of flu vaccination uptakes
A. Vila-Córcoles et al. [61]	2020	Spain	Retrospective cohort study/Adults- general population	rt-PCR	79,083	HR	1.02 (95% CI: 0.79-1.32)	age, sex, comorbidities, residence and vaccination history
I. Green et al. [62]	2020	Israel	Retrospective cohort study/Adults- general population	rt-PCR	19,089	OR	0.79 (95% CI: 0.67-0.98)	age, gender, ethnicity, underlying medical conditions, obesity, and smoking status
E. Kissling et al. [15]	2021	Europe	Case-control study (multicenter)/Adults-general population	rt-PCR	2,147	OR	0.93 (95% CI: 0.66-1.32)	age, sex and chronic conditions, time of swab test
A. Conlon et al. [63]	2021	USA	Retrospective cohort study/Adults- general population	rt-PCR	27,201	OR	0.76 (95% CI: 0.68-0.86)	age, sex, ethnicity, race, BMI, Elixhauser score, comorbidities, smoking status
B. Erismis et al. [30]	2021	Turkey	Retrospective cohort study/Health	Not specified	203	RR	0.83 (95% CI: 0.75-0.93)	sex

			workers					
A. Bozek et al. [64]	2021	Poland	Retrospective cohort study (multicenter)/Adults-general population	rt-PCR	2,558	HR	0.74 (95% CI: 0.54-0.89)	age , sex, comorbidities, high economic status, BCG vaccination in the past
M. Kowalskaet al.	2021	Poland	Cross-sectional study/Adults- general population	IgG antibodies	5,376	OR	0.68 (95% CI: 0.55-0.83)	age, sex, comorbidities, previous COVID-19 contact or quarantine
M. Fernández- Prada et al. [66]	2021	Spain	Case-control study/Adults-general population	rt-PCR	188	OR	1.70 (95% CI: 0.97-3.25)	age, sex, patient location
K. Huang et al. [34]	2021	USA	Cross-sectional study/Old adults	Not specified	55,667,997	OR	0.76 (95% CI: 0.75-0.77)	age, sex, comorbidities
J. P. King et al. [67]	2021	USA	Prospective cohort study/Adults- general population	rt-PCR	1,356	OR	0.83 (95% CI: 0.63-1.10)	age ,sample collection interval, sex, high-risk condition and month of onset
C. Pawlowski et al. [68]	2021	USA	Retrospective cohort study/Adults- general population	rt-PCR	12,791	RR	0.85 (95% CI: 0.75-0.96)	age, gender, race, ethnicity, county level COVID-19 incidence rate county-level COVID-19 test positive rate, Elixhauser comorbidities, pregnancy, number of other vaccines
S. Caratozzoloet al.	2020	Italy	Retrospective cohort study/Old adults	rt-PCR/or infection according to WHO definition	848	OR	0.47 (95% CI: 0.29-0.74)	age, sex, comorbidities, clinical dementia rating scale
M. N. Rivas et al. [29]	2021	USA	Retrospective cohort study/Health workers	IgG antibodies	6,087	OR	1.84 (95% CI: 0.57-11.3)	age, sex
J. G. Zein et al. [69]	2020	USA	Prospective cohort study/Adults- general population	Not specified	13,220	OR	0.79 (95% CI: 0.62-1.00)	age, sex, race and comorbidities
P. A. Debisarun et al. [37]	2020	Netherlands	Retrospective cohort study/Health workers	rt-PCR	6,856	RR	0.61 (95% CI: 0.46-0.82)	age

			Prospective cohort study/Adults-	Laboratory				age, sex, ethnic group, comorbidities, socioeconomic status, smoking status,
			1	•				
Y. Xiang et al. [70]	2020	UK	general population	confirmed	30,835	OR	0.60 (95% CI: 0.53-0.68)	anthropometric measures
								age, sex, comorbidities,
M. Alkathlan et al.		Saudi	Cross-sectional study/Health	Laboratory				nationality, educational
[71]	2021	Arabia	workers	confirmed	424	OR	0.83 (95% CI: 0.51-1.35)	level, flu vaccine efficacy

OR=adjusted odds ratio, HR=hazard odds ratio, RR=relative risk, rt-PCR=Reverse transcription polymerase chain reaction

medRxiv preprint doi: https://doi.org/10.1101/2022.06.30.22277089; this version posted June 30, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

All rights reserved. No reuse allowed without permission.

Table 2 Baseline characteristics of the 17 publications involving studies that assessed the association between influenza vaccination and COVID-19clinical outcomes: (15 studies for hospitalization, 4 for Mechanical Ventilation/invasive respiratory support, 11 for Intensive care and 18 for mortality).

First Author's name	Year of publication	Country	Study design	Identification of COVID-19	Sample size	Effect size	Adjusted estimate	Adjusted factors
			He	OSPITALIZATION				
P. D. Pedote et al. [72]	2021	Italy	Retrospective cohort study	rt-PCR	662	OR	1.20 (95% CI: 0.70-1.90)	age, sex, chronic disease
R. Pastorino et al. [36]	2021	Italy	Prospective cohort study	rt-PCR	741	OR	1.03 (95% CI: 0.66-1.62)	age, sex, comorbidities
C. Pawlowski et al. [68]	2021	USA	Retrospective cohort study	rt-PCR	959	RR	1.10 (95% CI: 0.83-1.50)	age, gender, race, ethnicity, county level COVID-19 incidence rate, county-level COVID-19 test positive rate, Elixhauser comorbidities, pregnancy, number of other vaccines
M. Gobbato et al. [73]	2020	Italy	Retrospective cohort study	Laboratory confirmed	3,010	OR	0.78 (95% CI: 0.61-1.01)	age, sex, comorbidities, medication, health district
M-J. Yang et al. [74]	2020	USA	Retrospective cohort study (single-centered)	Laboratory confirmed	2,005	OR	0.41 (95% CI: 0.28-0.59)	age, sex, ethnicity/race, comorbidities
S. Greco et al. [38]	2021	Italy	Retrospective cohort study (multicenter)	rt-PCR	952	OR	1.44 (95% CI: 1.01-2.05)	sex
A. Bozek et al. [64]	2021	Poland	Retrospective cohort study (multicenter)	rt-PCR	151	HR	0.48 (95% CI: 0.36-0.77)	age , sex, comorbidities, high economic status, BCG vaccination in the past
K. Huang et al. [34]	2021	USA	Cross-sectional study	Not specified	55,667,97 7	OR	0.76 (95% CI: 0.75-0.77)	age, sex, comorbidities
M. Massari et al. [75]	2021	Italy	Retrospective cohort study	rt-PCR	115,945	RR	0.87 (95% CI: 0.86-0.88)	age, sex, Charlson comorbidity index, ethnicity, drugs, comorbidities
A. Conlon et al. [63]	2021	USA	Retrospective cohort study	rt-PCR	1,218	OR	0.58 (95% CI: 0.46-0.73)	age, sex, ethnicity, race, BMI, Elixhauser score, comorbidities, smoking status

P. Ragni et al. [60]	2020	Italy	Prospective cohort study	rt-PCR	4,485	HR	1.00 (95% CI: 0.84-1.19)	age, comorbidities, exposure to influenza vaccination
C. R. Wilcox et al. [76]	2021	UK	Retrospective cohort study	rt-PCR	6,921	HR	0.85(95% CI: 0.75-0.97)	age, sex, BMI, socioeconomic status (IMD), smoking status, frailty score (electronic frailty index), pre-existing comorbidities and medication
J. G. Zein et al. [69]	2020	USA	Prospective cohort study	Not specified	1,434	OR	1.29 (95% CI: 0.72-2.31)	age, sex, race and comorbidities
I. Ilic et al. [77]	2020	Serbia	Retrospective cohort study	rt-PCR	107	OR	1.31 (95% CI: 0.54-3.17)	age, malignancy, hypertension, coronary artery disease, heart failure, diabetes mellitus, bronchial asthma, previous CVD, arrhythmia, BMI, current smoking
S. M. Taghioff et al. [78]	2021	Netherland s	Retrospective cohort study	Not specified	74,754	OR	1.07 (95% CI: 0.96-1.18)	age, race, ethnicity, gender, hypertension, diabetes, hyperlipidemia, chronic obstructive pulmonary disease (COPD), obesity, heart disease, and lifestyle habits such as smoking
			MECHANICAL VENTILAT	ION/INVANSIVE RE	SPIRATOR	Y SUPP	ORT	
G. Fink et al. [79]	2020	Brazil	Retrospective cohort study	rt-PCR	39,745	OR	0.83 (95% CI: 0.77-0.89)	age, sex, race, educational attainment, comorbidities, treatment facility
A. Conlon et al. [63]	2021	USA	Retrospective cohort study	rt-PCR	1,218	OR	0.45 (95% CI: 0.27-0.78)	age, sex, ethnicity, race, BMI, Elixhauser score, comorbidities, smoking status
A. E. Demkina et al. [80]	2020	Russia	Cohort study	Clinically confirmed/ rt-PCR	214,751	OR	0.74 (95% CI: 0.54-1.01)	age, patient's gender, comorbidities

A. Bozek et al. [64]	2021	Poland	Retrospective cohort study (multicenter)	rt-PCR	21	OR	0.42 (95% CI: 0.02-9.96)	age , sex, comorbidities, high economic status, BCG vaccination in the past
			INTI	ENSIVE CARE				
M-J. Yang et al. [74]	2021	USA	Retrospective cohort study (single-centered)	rt-PCR	2,005	OR	0.31 (95% CI: 0.07-0.85)	age, sex, ethnicity/race, comorbidities
M. Massari et al. [75]	2021	Italy	Retrospective cohort study	rt-PCR	111,740	RR	1.01 (95% CI: 0.99-1.04)	age, sex, comorbidities, ethnicity, drugs
R. Pastorino et al. [36]	2021	Italy	Prospective cohor tstudy	rt-PCR	99	OR	1.26 (95% CI: 0.74-2.21)	age, sex, comorbidities
A. Conlon et al. [63]	2021	USA	Retrospective cohort study	rt-PCR	1,218	OR	0.64 (95% CI: 0.41-1.00)	age, sex, ethnicity, race, BMI, Elixhauser score, comorbidities, smoking status
C. Pawlowski et al. [68]	2021	USA	Retrospective cohort study	rt-PCR	959	RR	1.10 (95% CI: 0.56-2.20)	age, gender, race, ethnicity, county level COVID-19 incidence rate, county-level COVID-19 test positive rate, Elixhauser comorbidities, pregnancy, number of other vaccines
G. Fink et al. [79]	2020	Brazil	Retrospective cohort study	rt-PCR	39,156	OR	0.93 (95% CI: 0.87-0.99)	age, sex, race, educational attainment, comorbidities, treatment facility
A. E. Demkina et al. [80]	2020	Russia	Retrospective cohort study	Clinically confirmed/ rt-PCR	214,751	OR	0.76 (95% CI: 0.59-0.97)	age, patient's gender, comorbidities
M. Candelli et al. [81]	2021	Italy	Retrospective cohort study	rt-PCR	602	OR	0.73 (95% CI: 0.35-1.56)	age, sex, comorbidities
M. L. de la Cruz Contyet al. [31]	2021	Spain	Prospective cohort study (multicenter)	rt-PCR	206	OR	1.92 (95% CI: 0.36-10.3)	age, sex, comorbidities
J. G. Zeinet al. [69]	2020	USA	Prospective cohort study	Not specified	1,434	OR	0.65 (95% CI: 0.22-1.79)	age, sex, race and comorbidities
S. M. Taghioff et al. [78]	2021	Netherland s	Retrospective cohort study	Not specified	74,754	OR	1.18 (95% CI: 1.00-1.39)	age, race, ethnicity, gender, hypertension, diabetes, hyperlipidemia, chronic obstructive pulmonary

								disease (COPD), obesity, heart disease, and lifestyle habits such as smoking
		1	•	MORTALITY				
S. Greco et al. [38]	2021	Italy	Retrospective cohort study	rt-PCR	952	OR	1.06 (95% CI: 0.60-1.88)	sex
P. D. Pedote et al. [72]	2021	Italy	Retrospective cohort study	rt-PCR	662	OR	1.60 (95% CI: 0.80-3.20)	age, sex, chronic diseases
R. Pastorino et al. [36]	2021	Italy	Prospective cohort study	rt-PCR	97	OR	1.33 (95% CI: 0.77-2.31)	age, sex, comorbidities
M. Massari et al. [75]	2021	Italy	Retrospective cohort study	rt-PCR	115,945	RR	1.04 (95% CI: 1.01-1.06)	age, sex, comorbidities, ethnicity, drugs
J. M. Fernadez. Ibánezet al. [82]	2021	Spain	Retrospective cohort study	rt-PCR	410	OR	1.55 (95% CI: 0.96-2.48)	sex,chronic diseases
A. Bozek et al. [64]	2021	Poland	Retrospective cohort study (multicenter)	rt-PCR	2,558	HR	0.74 (95% CI: 0.03-20.8)	age, sex, comorbidities, high economic status, BCG vaccination in the past
M. Candelli et al. [81]	2021	Italy	Retrospective cohort study	rt-PCR	602	OR	0.20 (95% CI: 0.08-0.51)	age, sex, comorbidities
A. Conlon et al. [63]	2021	USA	Retrospective cohort study	rt-PCR	1,218	HR	0.94 (95% CI: 0.61-1.47)	age, sex, ethnicity, race, BMI, Elixhauser score, comorbidities, smoking status
P. Ragni et al. [60]	2020	Italy	Prospective cohort study	rt-PCR	4,872	HR	1.14 (95% CI: 0.95-1.37)	age, comorbidities, exposure to influenza vaccination test
C. R Wilcox et al. [76]	2021	UK	Retrospective cohort study	rt-PCR	6,368	OR	0.76 (95% CI: 0.64-0.90)	age, sex, BMI, socioeconomic status (IMD), smoking status, frailty score (electronic frailty index), pre- existing comorbidities and medication
G. Fink et al. [79]	2020	Brazil	Retrospective cohort study	rt-PCR	53,752	OR	0.84 (95% CI: 0.78-0.91)	age, sex, race, educational attainment, comorbidities, treatment facility
A. E. Demkina et al. [80]	2020	Russia	Retrospective cohort study	Clinically confirmed/ rt-PCR	117,346	HR	0.78 (95% CI: 0.63-0.95)	age, patient's gender, comorbidities
Y. Azzi et al. [32]	2020	USA	Prospective cohor tstudy	rt-PCR	229	OR	0.88 (95% CI: 0.70-0.96)	age, type of kidney transplant
M. Gobbato et al. [73]	2020	Italy	Retrospective cohort study	Laboratory confirmed	3,010	OR	0.78 (95% CI: 0.61-1.01)	age, sex, comorbidities, medication, health district

J. G. Zeinet al. [69]	2020	USA	Prospective cohort study	Not specified	14,654	OR	0.98 (95% CI: 0.39-2.43)	age, sex, race and comorbidities
D. Giannoglou et al. [83]	2020	Greece	Cross-sectional study	Not specified	512	OR	0.38 (95% CI: 0.17-0.81)	age, gender, comorbidities
E. Ortiz-Prado et al. [84]	2020	Ecuador	Cross-sectional study	rt-PCR	9,468	RR	1.40 (95% CI: 0.46-4.28)	age, gender, comorbidities
S. M. Taghioff et al [78]	2021	Netherland s	Retrospective cohort study	Not specified	74,754	OR	0.89 (95% CI: 0.77-1.03)	age, race, ethnicity, gender, hypertension, diabetes, hyperlipidemia, chronic obstructive pulmonary disease (COPD), obesity, heart disease, and lifestyle habits such as smoking.

medRxiv preprint doi: https://doi.org/10.1101/2022.06.30.22277089; this version posted June 30, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

All rights reserved. No reuse allowed without permission.

Table 3 Baseline characteristics of a) 6 publications, involving 10 studies, that assessed the association between pneumococcal vaccination and SARS-CoV-2 infection, b) 4 studies that assessed that assessed the association between pneumococcal vaccination and the risk of hospitalization and c) 3 studies that assessed the association between pneumococcal vaccination and the risk of intensive care.

First Author's name	Year of publication	Country	Study design	Identification of COVID-19	Sample size	Effect size	Adjusted estimate	Adjusted factors
		1	-	INFECTION				
A. Vila-Córcoles et al. [61]	2020	Spain	Retrospective cohort study	rt-PCR	79,083	HR	1.02 (95% CI 0.78- 1.33)	age, sex, comorbidities, residence and vaccination history
M. Noale et al. [35]	2020	Italy	Cross-sectional study	rt-PCR	6,061	OR	0.61 (95% CI 0.41-0.91)	sex, age, comorbidities, education, area of residence, smoking status
M. Noale et al. [35]	2020	Italy	Cross-sectional study (>65 years)	rt-PCR	619	OR	0.56 (95% CI 0.33-0.95)	sex, age, comorbidities, education, area of residence, smoking status
C. Pawlowski et al. [68]	2021	USA	Retrospective cohort study	rt-PCR	4,693	RR	0.72 (95% CI 0.56-0.92)	age, gender, race, ethnicity, county level COVID-19 incidence rate, county-level COVID-19 test positive rate, Elixhauser comorbidities, pregnancy, number of other vaccines
C. Pawlowski et al. [68]	2021	USA	Retrospective cohort study	rt-PCR	4,636	RR	1.06 (95% CI 0.81-137)	age, gender, race, ethnicity, county level COVID-19 incidence rate, county-level COVID-19 test positive rate, Elixhauser comorbidities, pregnancy, number of other vaccines
M. N. Rivas et al. [29]	2021	USA	Retrospective cohort study	IgG antibodies	6,083	OR	0.99 (95% CI 0.71-1.36)	age, sex
M. Fernández-Prada et al. [66]	2021	Spain	Case-control study	rt-PCR	188	OR	0.40 (95% CI 0.17-1.01)	age, sex and patient location
M. Fernández-Prada et al. [66]	2021	Spain	Test-negative case-control study	rt-PCR	187	OR	0.70 (95% CI: 0.28- 2.10)	age, sex and patient location

M. Fernández-Prada							0.20 (95% CI: 0.06-	
et al. [66]	2021	Spain	Case-control study	rt-PCR	188	OR	1.18)	age, sex and patient location
								age, sex, ethnic group,
								comorbidities, socioeconomic
				T 1				status, smoking status,
V V'	2020	1117	Donous discount of the de-	Laboratory	20.925	OD	0.5 (050) CL 0.21 0.92)	anthropometric measures
Y. Xiang et al. [70]	2020	UK	Prospective cohort study	confirmed HOSPITALIZA	30,835	OR	0.5 (95% CI: 0.31-0.82)	
				HOSFITALIZA	HON			
								age, sex, comorbidities,
				Laboratory				medication, health district
M. Gobbato et al. [73]	2020	Italy	Retrospective cohort	confirmed	3,010	OR	1.53 (95% CI:1.91-1.97)	
R. Pastorino et al.	2021	7. 1	B	, DCD		O.D.	0.96 (95% CI: 0.53-	1.11.1
[36]	2021	Italy	Prospective cohort study	rt-PCR	741	OR	1.78)	age, sex, comorbidities
								age, gender, race, ethnicity,
								county level COVID-19
								incidence rate, county-level
								COVID-19 test positive rate,
								Elixhauser comorbidities,
C. Pawlowski et al.	2021	****		D. CD			1.30 (95% CI: 0.86-	pregnancy, number of other
[68]	2021	USA	Retrospective cohort study	rt-PCR	277	RR	2.10)	vaccines
								age, gender, race, ethnicity, county level COVID-19
								incidence rate, county-level
								COVID-19 test positive rate,
								Elixhauser comorbidities,
C.Pawlowski et al.							1.20 (95% CI: 0.71-	pregnancy, number of other
[68]	2021	USA	Retrospective cohort study	rt-PCR	282	RR	2.20)	vaccines
			<u> </u>	INTENSIVE CAR	E UNIT			
R. Pastorino et al.							0.75 (95% CI: 0.35-	
[36]	2021	Italy	Prospective cohortstudy	rt-PCR	741	OR	1.61)	age, sex, comorbidities
• 1							,	vaccinated and unvaccinated
								propensity score matching;
								demographics (age, gender, race,
C .Pawlowski et al.							1.40 (95% CI: 0.48-	ethnicity), county level COVID-
[68]	2021	USA	Retrospective cohort study	rt-PCR	254	RR	3.90)	19 incidence rate, county-level

medRxiv preprint doi: https://doi.org/10.1101/2022.06.30.22277089; this version posted June 30, 2022. The copyright holder for this prep (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

								COVID-19 test positive rate,
								Elixhauser comorbidities,
								pregnancy, number of other
								vaccines
								age, gender, race, ethnicity,
								county level COVID-19
								incidence rate, county-level
								COVID-19 test positive rate,
								Elixhauser comorbidities,
C.Pawlowski et al.							1.10 (95% CI: 0.46-	pregnancy, number of other
[68]	2021	USA	Retrospective cohort study	rt-PCR	236	RR	2.40)	vaccines

Table 4 Effect sizes, heterogeneity statistics and results for publications bias of the association between influenza vaccination, SARS-CoV-2 infection as well as clinical outcomes.

Outcomes	No. of studies	Adjusted estimates (95% CI)	<i>p</i> -value	<i>I</i> ² value (%)	Bias (p-value)
SARS-CoV-2 infection	22	0.80 (0.75-0.86)	<0.01	70.1	Begg's test: 0.82 Egger's test: 0.19
Hospitalization	15	0.88 (0.81-0.95)	<0.01	95.1	Begg's test: 0.55 Egger's test: 0.62
Mechanical Ventilation/invasive respiratory support	4	0.73(0.58-0.92)	0.01	42.4	Begg's test: 0.73 Egger's test: 0.21
Intensive care unit admission	11	0.96 (0.88-1.06)	0.40	86.0	Begg's test: 0.76 Egger's test: 0.14
Mortality	18	0.90 (0.81-1.01)	0.07	78.2	Begg's test: 0.82 Egger's test: 0.07

Table 5 Subgroup analysis of the association between influenza vaccination and SARS-CoV-2 infection.

Subgroup variables	No. of	Adjusted estimate (95% CI)	<i>p</i> -value	I ² value
	studies			(%)
	,	Study Design		
cross sectional study	5	0.76 (0.75-0.77)	< 0.01	0.00
retrospective cohort study	10	0.80 (0.75-0.86)	< 0.01	41.5
prospective cohort study	4	0.80 (0.56-1.08)	0.14	90.9
case-control study	3	0.99 (0.76-1.23)	0.93	51.7
	Stu	udy Population		
adults-general population	13	0.80 (0.74-0.87)	< 0.01	68.4
older adults	3	0.72 (0.56-0.92)	0.01	53.8
Health workers	6	0.84 (0.68-1.04)	0.12	66.6
		Effect Size		
OR	17	0.80 (0.74-0.87)	< 0.01	72.5
RR/HR	5	0.82 (0.73-0.92)	< 0.01	46.4
	Adj	ustment Factors		
age/sex/age and sex	5	0.86 (0.62-1.21)	0.40	63.5
age, sex and comorbidities	9	0.82 (0.73-0.92)	< 0.01	78.4
age, sex, comorbidities, and socioeconomic status, education or residence	6	0.87 (0.68-1.11)	.11) 0.26	
,	C	COVID-19 test		
rt-PCR	15	0.84 (0.77-0.92)	< 0.01	57.7
IgG/IgM antibodies	2	0.83 (0.38-1.82)	0.64	37.9
Laboratory confirmed (not specified)	5	0.74 (0.66-0.83)	0.74 (0.66-0.83) <0.01	
		Continent		- "
Europe	13	0.81 (0.70-0.93)	< 0.01	79.7
N. America	6	0.76 (0.75-0.77)	< 0.01	0.00
Asia	3	0.83 (0.77-0.90)	< 0.01	0.00

Table 6 Subgroup analysis of the association between influenza vaccination and COVID-19 clinical outcomes.

Subgroup variables	No. of studies	Adjusted estimate	<i>p</i> -value	I ² valu
		(95% CI)		(%)
	HOSPITAI	LIZATION		1
	Effec	t Size		
OR	10	0.92 (0.78-1.02)	0.40	86.6
RR/HR	5	0.87 (0.71-0.99)	0.03	71.0
	Adjusted	l Factors		1
age/sex/age and sex	1	1.44 (1.00-2.07)	0.05	89.8
age, sex and comorbidities	7	0.85 (0.71-1.03)	0.49	66.3
	COVID	9-19 test		
rt-PCR	10	0.89 (0.78-1.02)	0.09	74.6
Laboratory confirmed/(not	5	0.88 (0.67-1.12)	0.30	90.0
specified)	3	U.00 (U.U/-1.12)	0.30	90.0
	Cont	inent	_1	1
Europe	10	0.93 (0.83-1.04)	0.21	75.7
N. America	5	0.80 (0.63-1.02)	0.07	73.1
	INTENSIVE	CARE UNIT		
	Effec	t Size		
OR	9	0.91 (0.76-1.08)	0.26	55.9
		0.91 (0.70-1.08)	0.20	33.9
HR	2	1.01 (0.99-1.04)	0.20	0.0
		1.01 (0.99-1.04)		
	2	1.01 (0.99-1.04)		
HR rt-PCR	2 COVID	1.01 (0.99-1.04) 0-19 test 0.93 (0.84-1.03)	0.43	58.5
HR rt-PCR	2 COVID	1.01 (0.99-1.04) 0-19 test	0.43	0.0
HR rt-PCR Laboratory confirmed/(not	2 COVID	1.01 (0.99-1.04) 0-19 test 0.93 (0.84-1.03) 1.12 (0.80-1.57)	0.43	58.5
HR rt-PCR Laboratory confirmed/(not specified)	2 COVID 9 2	1.01 (0.99-1.04) 0-19 test 0.93 (0.84-1.03) 1.12 (0.80-1.57)	0.43	58.5
HR rt-PCR Laboratory confirmed/(not specified)	COVID 9 2 Adjusted	1.01 (0.99-1.04) 1-19 test 0.93 (0.84-1.03) 1.12 (0.80-1.57) 1 Factors 0.87 (0.65-1.17)	0.43	58.5
HR rt-PCR Laboratory confirmed/(not specified)	COVID 9 2 Adjusted	1.01 (0.99-1.04) 1-19 test 0.93 (0.84-1.03) 1.12 (0.80-1.57) 1 Factors 0.87 (0.65-1.17)	0.43	58.5
rt-PCR Laboratory confirmed/(not specified) age, sex and comorbidities	COVID 9 2 Adjusted 4 Cont	1.01 (0.99-1.04) 1-19 test 0.93 (0.84-1.03) 1.12 (0.80-1.57) 1 Factors 0.87 (0.65-1.17) inent	0.43 0.14 0.52	0.0 58.5 14.1
rt-PCR Laboratory confirmed/(not specified) age, sex and comorbidities Europe N. America	COVID 9 2 Adjusted 4 Cont	1.01 (0.99-1.04) 1-19 test 0.93 (0.84-1.03) 1.12 (0.80-1.57) 1 Factors 0.87 (0.65-1.17) inent 1.05 (0.95-1.16) 0.69 (0.47-1.02)	0.43 0.14 0.52 0.35 0.32 0.06	0.0 58.5 14.1 17.6
rt-PCR Laboratory confirmed/(not specified) age, sex and comorbidities Europe N. America S. America	2 COVID 9 2 Adjusted 4 Cont	1.01 (0.99-1.04) 1-19 test 0.93 (0.84-1.03) 1.12 (0.80-1.57) 1 Factors 0.87 (0.65-1.17) inent 1.05 (0.95-1.16) 0.69 (0.47-1.02) 0.93 (0.87-0.99)	0.43 0.14 0.52 0.35 0.32 0.06 0.02	0.0 58.5 14.1 17.6
rt-PCR Laboratory confirmed/(not specified) age, sex and comorbidities Europe N. America	2 COVID 9 2 Adjusted 4 Cont	1.01 (0.99-1.04) 1-19 test 0.93 (0.84-1.03) 1.12 (0.80-1.57) 1 Factors 0.87 (0.65-1.17) inent 1.05 (0.95-1.16) 0.69 (0.47-1.02) 0.93 (0.87-0.99) 0.76 (0.59-0.98)	0.43 0.14 0.52 0.35 0.32 0.06	0.0 58.5 14.1 17.6
rt-PCR Laboratory confirmed/(not specified) age, sex and comorbidities Europe N. America S. America	2 COVID 9 2 Adjusted 4 Cont 5 4 1 1 MORT	1.01 (0.99-1.04) 1-19 test 0.93 (0.84-1.03) 1.12 (0.80-1.57) 1 Factors 0.87 (0.65-1.17) inent 1.05 (0.95-1.16) 0.69 (0.47-1.02) 0.93 (0.87-0.99) 0.76 (0.59-0.98) ALITY	0.43 0.14 0.52 0.35 0.32 0.06 0.02	0.0 58.5 14.1 17.6
rt-PCR Laboratory confirmed/(not specified) age, sex and comorbidities Europe N. America S. America	2 COVID 9 2 Adjusted 4 Cont	1.01 (0.99-1.04) 1-19 test 0.93 (0.84-1.03) 1.12 (0.80-1.57) 1 Factors 0.87 (0.65-1.17) inent 1.05 (0.95-1.16) 0.69 (0.47-1.02) 0.93 (0.87-0.99) 0.76 (0.59-0.98) ALITY	0.43 0.14 0.52 0.35 0.32 0.06 0.02	0.0 58.5 14.1 17.6

rt-PCR	14	0.93 (0.82-1.06)	0.27	80.3			
Laboratory confirmed/(not specified)	4	0.81 (0.65-1.00)	0.05	37.1			
	Adjusto	ed Factors					
age/sex/age and sex	3	1.07 (0.75-1.53)	0.70	59.2			
age, sex and comorbidities	8	0.82 (0.61-1.10)	0.19	75.3			
Continent							
Europe	12	0.94 (0.80-1.09)	0.40	75.3			
N. America	3	0.89 (0.76-1.03)	0.12	0.0			
S. America	2	0.84 (0.78-0.91)	< 0.01	0.0			
Asia	1	0.78 (0.63-0.95)	0.02	-			

Table 7 Effect sizes, heterogeneity statistics and results for publications bias of the association between pneumococcal vaccination and SARS-CoV-2 infection and outcomes.

Outcomes	No. of studies	Adjusted estimates (95% CI)	<i>p</i> -value	<i>I</i> ² value (%)	Bias (p-value)
SARS-Co V-2 infection	10	0.70 (0.57-0.88)	<0.01	47.2	Begg's test: 0.37 Egger's test: 0.11
Hospitalization	4	1.47 (1.30-1.67)	<0.01	11.4	Begg's test: 0.09 Egger's test: 0.05
Intensive care unit admission	3	0.99 (0.60- 1.64)	0.96	0.0	Begg's test: 0.30 Egger's test: 0.30